SummitTX Capital’s Roivant Sciences ROIV Stock Holding History

SummitTX Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.53M	Buy	+128,095	New	+$3.79M	0.12%	199
2026 Q1	–	Sell	-65,887	Closed	-$1.43M	–	943
2025 Q4	$1.43M	Sell	65,887 -39,196	-37%	-$773K	0.04%	354
2025 Q3	$1.59M	Buy	105,083 +43,252	+70%	+$535K	0.07%	302
2025 Q2	$697K	Sell	61,831 -80,486	-57%	-$872K	0.03%	441
2025 Q1	$1.44M	Buy	+142,317	New	+$1.54M	0.06%	316

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

SummitTX Capital's ROIV Position: Q2 2026 in Review

SummitTX Capital opened a new position in Roivant Sciences (ROIV) in Q2 2026: 128,095 shares worth $4.53M. The stake represents 0.12% of the portfolio and ranks #199 among its holdings. This is a return to the name: SummitTX Capital previously reported a position in ROIV as recently as Q4 2025.

SummitTX Capital first reported a position in ROIV in Q1 2025 and has held it in 5 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

SummitTX Capital held 128,095 shares of Roivant Sciences worth $4.53M as of Q2 2026.
Roivant Sciences was a new SummitTX Capital position in Q2 2026.
Roivant Sciences made up 0.12% of SummitTX Capital's portfolio in Q2 2026, its #199 holding.
SummitTX Capital first reported a position in Roivant Sciences in Q1 2025 and has held it in 5 quarters since.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.